Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NEPHROS INC Major Shareholding Notification 2007

Feb 9, 2007

34594_mrq_2007-02-09_e260c4c8-263d-4bed-9d41-c230379b93e9.zip

Major Shareholding Notification

Open in viewer

Opens in your device viewer

SC 13G/A 1 kl02061.htm SCHEDULE 13G AMENDMENT NO. 2 Schedule 13G Amendment No. 2 Licensed to: Kramer Levin Naftalis & Frankel LLP Document Created using EDGARizer HTML 3.0.4.0 Copyright 2006 EDGARfilings, Ltd., an IEC company. All rights reserved EDGARfilings.com

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2)

Nephros, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

640671103

(CUSIP Number)

December 31, 2006

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

¨ Rule 13d-1(c)

ý Rule 13d-1(d)

Page 1 of 5

SCHEDULE 13G

CUSIP No. 640671103

| 1) — 2) | NAME
OF REPORTING PERSON S.S.
OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Eric
A. Rose, M.D. — CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP | | (a) ¨ (b) ¨ |
| --- | --- | --- | --- |
| 3) | SEC
USE ONLY | | |
| 4) | CITIZENSHIP
OR PLACE OF ORGANIZATION United
States | | |
| | NUMBER OF SHARES BENEFICIALLY OWNED
BY EACH REPORTING PERSON WITH | 5) | SOLE
VOTING POWER 905,192 |
| | | 6) | SHARED
VOTING POWER 0 |
| | | 7) | SOLE
DISPOSITIVE POWER 905,192
|
| | | 8) | SHARED
DISPOSITIVE POWER 0 |
| 9) | AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 905,192* | | |
| 10) | CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES ¨ | | |
| 11) | PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.3% | | |
| 12) | TYPE
OF REPORTING PERSON IN | | |

  • Includes 160,041 shares of the Issuer’s common stock issuable upon exercise of options granted to Dr. Rose under the Issuer's 2000 and 2004 Equity Incentive Plans, which have vested or are scheduled to vest within 60 days of December 31, 2006.

Page 2 of 5

Schedule 13G

Item 1(a). Name of Issuer:

Nephros, Inc.

Item 1(b). Address of Issuer’s Principal Executive Offices:

3960 Broadway

New York, New York 10032

Item 2(a). Name of Person Filing : Eric A. Rose, M.D.

Item 2(b). Address of Principal Business Office or, if None, Residence:

177 Fort Washington Ave.

7th Floor, Room 435

New York, New York 10032

Item 2(c). Citizenship: United States

Item 2(d). Title of Class of Securities:

Common Stock, par value $.001 per share

Item 2(e). CUSIP Number: 640671103

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

(a) ¨ Broker or Dealer Registered Under Section 15 of the Act (15 U.S.C. 78o)

(b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c)

(c) ¨ Insurance Company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c)

(d) ¨ Investment Company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)

(e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E)

(f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F)

(g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G)

(h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813)

(i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)

Page 3 of 5

(j) ¨ Group, in accordance with §240.13d-1(b)(ii)(J)

Item 4. Ownership.

(a) Amount beneficially owned: 905,192*

(b) Percent of class: 7.3%

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote: 905,192*

(ii) Shared power to vote or to direct the vote: None

(iii) Sole power to dispose or to direct the disposition of: 905,192*

(iv) Shared power to dispose or to direct the disposition of: None

* Includes 160,041 shares of the Issuer’s common stock issuable upon exercise of options granted to Dr. Rose under the Issuer's 2000 and 2004 Equity Incentive Plans, which have vested or are scheduled to vest within 60 days of December 31, 2006.

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

Not applicable

Item 8. Identification and Classification of Members of the Group.

Not applicable

Item 9. Notice of Dissolution of Group.

Not applicable

Item 10. Certification.

Not applicable

Page 4 of 5

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 9, 2007

Date

/s/ Eric A. Rose, M.D.

Eric A. Rose, M.D.

Page 5 of 5